Is RCEL or NRXS more profitable?

Avita Medical has a net margin of -56.96% compared to NeurAxis' net margin of -492.76%. Company Net Margins Return on Equity Return on Assets Avita Medical -56.96% N/A -78.53% NeurAxis -492.76% N/A -641.25%

Does the media prefer RCEL or NRXS?

In the previous week, NeurAxis had 6 more articles in the media than Avita Medical. MarketBeat recorded 8 mentions for NeurAxis and 2 mentions for Avita Medical. Avita Medical's average media sentiment score of 1.16 beat NeurAxis' score of 0.59 indicating that Avita Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avita Medical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRXS or OBIO more profitable?

Orchestra BioMed has a net margin of -184.60% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Orchestra BioMed -184.60% -149.61% -54.15%

Does the media favor NRXS or OBIO?

In the previous week, Orchestra BioMed had 2 more articles in the media than NeurAxis. MarketBeat recorded 10 mentions for Orchestra BioMed and 8 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.59 beat Orchestra BioMed's score of 0.39 indicating that NeurAxis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NRXS or CLPT more profitable?

ClearPoint Neuro has a net margin of -81.76% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat ClearPoint Neuro's return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% ClearPoint Neuro -81.76% -188.09% -40.88%

Does the media refer more to NRXS or CLPT?

In the previous week, NeurAxis had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 8 mentions for NeurAxis and 4 mentions for ClearPoint Neuro. NeurAxis' average media sentiment score of 0.59 beat ClearPoint Neuro's score of 0.20 indicating that NeurAxis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NRXS or CV more profitable?

CapsoVision has a net margin of -214.74% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% CapsoVision -214.74% -177.85% -135.07%

Does the media favor NRXS or CV?

In the previous week, NeurAxis had 5 more articles in the media than CapsoVision. MarketBeat recorded 8 mentions for NeurAxis and 3 mentions for CapsoVision. NeurAxis' average media sentiment score of 0.59 beat CapsoVision's score of 0.47 indicating that NeurAxis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NRXS or TMCI?

In the previous week, NeurAxis had 6 more articles in the media than Treace Medical Concepts. MarketBeat recorded 8 mentions for NeurAxis and 2 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 0.67 beat NeurAxis' score of 0.59 indicating that Treace Medical Concepts is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Treace Medical Concepts 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeurAxis (NRXS) Competitors

$7.15 +0.04 (+0.56%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$7.18 +0.03 (+0.42%)

As of 10/5/2026 07:30 PM Eastern

Compare

NRXS vs. RCEL, OBIO, CLPT, CV, and TMCI

Should you buy NeurAxis stock or one of its competitors? NeurAxis's main competitors and comparable companies include Avita Medical (RCEL), Orchestra BioMed (OBIO), ClearPoint Neuro (CLPT), CapsoVision (CV), and Treace Medical Concepts (TMCI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeurAxis compare to Avita Medical?

Avita Medical (NASDAQ:RCEL) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Avita Medical has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

NeurAxis has lower revenue, but higher earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$71.61M	5.70	-$48.59M	-$1.44	N/A
NeurAxis	$5.32M	16.89	-$14.63M	-$0.78	N/A

27.7% of Avita Medical shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 2.2% of Avita Medical shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, NeurAxis had 6 more articles in the media than Avita Medical. MarketBeat recorded 8 mentions for NeurAxis and 2 mentions for Avita Medical. Avita Medical's average media sentiment score of 1.16 beat NeurAxis' score of 0.59 indicating that Avita Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avita Medical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avita Medical has a net margin of -56.96% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
NeurAxis	-492.76%	N/A	-641.25%

Avita Medical currently has a consensus price target of $11.40, suggesting a potential downside of 13.96%. NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 81.82%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

NeurAxis beats Avita Medical on 8 of the 15 factors compared between the two stocks.

How does NeurAxis compare to Orchestra BioMed?

NeurAxis (NASDAQ:NRXS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Orchestra BioMed has a net margin of -184.60% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

NeurAxis has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Orchestra BioMed had 2 more articles in the media than NeurAxis. MarketBeat recorded 10 mentions for Orchestra BioMed and 8 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.59 beat Orchestra BioMed's score of 0.39 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeurAxis currently has a consensus target price of $13.00, indicating a potential upside of 81.82%. Orchestra BioMed has a consensus target price of $13.17, indicating a potential upside of 118.35%. Given Orchestra BioMed's higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

NeurAxis has higher earnings, but lower revenue than Orchestra BioMed. NeurAxis is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	16.89	-$14.63M	-$0.78	N/A
Orchestra BioMed	$33.48M	10.82	-$52.70M	-$0.85	N/A

Summary

NeurAxis beats Orchestra BioMed on 9 of the 16 factors compared between the two stocks.

How does NeurAxis compare to ClearPoint Neuro?

NeurAxis (NASDAQ:NRXS) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, NeurAxis had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 8 mentions for NeurAxis and 4 mentions for ClearPoint Neuro. NeurAxis' average media sentiment score of 0.59 beat ClearPoint Neuro's score of 0.20 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeurAxis has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

NeurAxis has higher earnings, but lower revenue than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	16.89	-$14.63M	-$0.78	N/A
ClearPoint Neuro	$36.97M	9.50	-$25.54M	-$1.18	N/A

ClearPoint Neuro has a net margin of -81.76% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

NeurAxis presently has a consensus price target of $13.00, indicating a potential upside of 81.82%. ClearPoint Neuro has a consensus price target of $25.67, indicating a potential upside of 122.80%. Given ClearPoint Neuro's higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

NeurAxis beats ClearPoint Neuro on 10 of the 16 factors compared between the two stocks.

How does NeurAxis compare to CapsoVision?

NeurAxis (NASDAQ:NRXS) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

11.8% of NeurAxis shares are held by institutional investors. 21.1% of NeurAxis shares are held by insiders. Comparatively, 2.3% of CapsoVision shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NeurAxis has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, CapsoVision has a beta of -2.45, suggesting that its stock price is 345% less volatile than the broader market.

In the previous week, NeurAxis had 5 more articles in the media than CapsoVision. MarketBeat recorded 8 mentions for NeurAxis and 3 mentions for CapsoVision. NeurAxis' average media sentiment score of 0.59 beat CapsoVision's score of 0.47 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeurAxis presently has a consensus target price of $13.00, indicating a potential upside of 81.82%. CapsoVision has a consensus target price of $9.50, indicating a potential upside of 44.16%. Given NeurAxis' stronger consensus rating and higher possible upside, research analysts clearly believe NeurAxis is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

CapsoVision has a net margin of -214.74% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
CapsoVision	-214.74%	-177.85%	-135.07%

NeurAxis has higher earnings, but lower revenue than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	16.89	-$14.63M	-$0.78	N/A
CapsoVision	$13.89M	23.74	-$25.32M	-$0.47	N/A

Summary

NeurAxis beats CapsoVision on 10 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Treace Medical Concepts?

NeurAxis (NASDAQ:NRXS) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, NeurAxis had 6 more articles in the media than Treace Medical Concepts. MarketBeat recorded 8 mentions for NeurAxis and 2 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 0.67 beat NeurAxis' score of 0.59 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Treace Medical Concepts	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeurAxis presently has a consensus price target of $13.00, indicating a potential upside of 81.82%. Treace Medical Concepts has a consensus price target of $5.17, indicating a potential upside of 15.40%. Given NeurAxis' stronger consensus rating and higher probable upside, research analysts plainly believe NeurAxis is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NeurAxis has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Treace Medical Concepts has a net margin of -28.99% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

NeurAxis has higher earnings, but lower revenue than Treace Medical Concepts. NeurAxis is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	16.89	-$14.63M	-$0.78	N/A
Treace Medical Concepts	$212.69M	1.37	-$59M	-$0.93	N/A

Summary

NeurAxis beats Treace Medical Concepts on 8 of the 15 factors compared between the two stocks.

Get NeurAxis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXS vs. The Competition

Export

Metric	NeurAxis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$89.79M	$5.42B	$7.14B	$13.26B
Dividend Yield	N/A	1.79%	2.53%	17.36%
P/E Ratio	-3.89	25.77	274.34	26.20
Price / Sales	16.89	69.15	577.57	78.96
Price / Cash	N/A	32.73	27.22	34.70
Price / Book	-26.48	6.04	11.23	6.40
Net Income	-$14.63M	$146.97M	$3.49B	$381.07M
7 Day Performance	-7.86%	-0.38%	-1.33%	-0.30%
1 Month Performance	19.97%	-4.20%	-5.99%	-4.53%
1 Year Performance	126.98%	2.14%	7.27%	1.62%

NeurAxis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXS NeurAxis	1.9649 of 5 stars	$7.15 +0.6%	$13.00 +81.8%	+124.8%	$89.79M	$5.32M	N/A	24	News Coverage Analyst Revision
RCEL Avita Medical	1.0718 of 5 stars	$11.73 -1.9%	$11.40 -2.8%	+139.2%	$368.09M	$71.61M	N/A	226	Positive News
OBIO Orchestra BioMed	3.8813 of 5 stars	$6.22 +2.3%	$13.17 +111.7%	+122.5%	$365.44M	$33.48M	N/A	4	Analyst Forecast
CLPT ClearPoint Neuro	1.7551 of 5 stars	$12.21 +3.7%	$25.67 +110.2%	-57.9%	$359.04M	$36.97M	N/A	172	News Coverage
CV CapsoVision	3.3726 of 5 stars	$6.46 -3.4%	$9.50 +47.1%	+37.6%	$334.81M	$13.55M	N/A	99

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXS) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeurAxis (NRXS) Competitors

NRXS vs. RCEL, OBIO, CLPT, CV, and TMCI

How does NeurAxis compare to Avita Medical?

Summary

How does NeurAxis compare to Orchestra BioMed?

Summary

How does NeurAxis compare to ClearPoint Neuro?

Summary

How does NeurAxis compare to CapsoVision?

Summary

How does NeurAxis compare to Treace Medical Concepts?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeurAxis (NRXS) Competitors

NRXS vs. RCEL, OBIO, CLPT, CV, and TMCI

How does NeurAxis compare to Avita Medical?

Which has more risk & volatility, RCEL or NRXS?

Which has stronger valuation and earnings, RCEL or NRXS?

Do insiders and institutionals have more ownership in RCEL or NRXS?

Does the media prefer RCEL or NRXS?

Is RCEL or NRXS more profitable?

Do analysts rate RCEL or NRXS?

Summary

How does NeurAxis compare to Orchestra BioMed?

Is NRXS or OBIO more profitable?

Which has more risk and volatility, NRXS or OBIO?

Do insiders & institutionals believe in NRXS or OBIO?

Does the media favor NRXS or OBIO?

Do analysts rate NRXS or OBIO?

Which has stronger earnings & valuation, NRXS or OBIO?

Summary

How does NeurAxis compare to ClearPoint Neuro?

Do institutionals and insiders believe in NRXS or CLPT?

Does the media refer more to NRXS or CLPT?

Which has more volatility and risk, NRXS or CLPT?

Which has better valuation & earnings, NRXS or CLPT?

Is NRXS or CLPT more profitable?

Do analysts rate NRXS or CLPT?

Summary

How does NeurAxis compare to CapsoVision?

Do institutionals & insiders believe in NRXS or CV?

Which has more risk and volatility, NRXS or CV?

Does the media favor NRXS or CV?

Do analysts prefer NRXS or CV?

Is NRXS or CV more profitable?

Which has better earnings & valuation, NRXS or CV?

Summary

How does NeurAxis compare to Treace Medical Concepts?

Does the media favor NRXS or TMCI?

Do analysts prefer NRXS or TMCI?

Do institutionals and insiders believe in NRXS or TMCI?

Which has more risk & volatility, NRXS or TMCI?

Is NRXS or TMCI more profitable?

Which has higher valuation & earnings, NRXS or TMCI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools